[Using regulatory peptide imunofan in type 2 diabetes mellitus patients with diabetic foot syndrome].

What does this source report?

The randomized report describes immune, clinical and quality-of-life improvements with adjunctive Imunofan.

Population and setting

69 people with type 2 diabetes and diabetic foot: 39 adjunctive Imunofan, 30 basic-care controls

Evidence type

Randomized trial

Preparation

See the original report; formulation details require verification.

Source language

English indexed abstract; original language:

Title provenance

Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

What are the limitations?

• The abstract provides no numerical treatment effect, concealment or blinding details; no claim of fewer amputations follows.
• Full methods, reporting completeness and independent replication remain to be appraised.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Review depth: Abstract reviewed

Source access and review scope

Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.

Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.

Source provenance: Original journal report

Open original source or index record ↗

Cite and trace this record

Original source: Tutel'ian AV, Iakubovskaia IA, Skrypnik NV, Levedev VV. [Using regulatory peptide imunofan in type 2 diabetes mellitus patients with diabetic foot syndrome]. Terapevticheskii arkhiv · PMID 20481041 2009.

Molekul research summary: https://molekul.io/research/audit-20481041. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Related compound profiles